1365-2133/asset/cover.gif?v=1&s=413074e1e506a67a21dcc4e2de9ff9b6ce256d16 "British Journal of Dermatology")
A list of the dermatologists who took part in the trials appears on page 202.
1365-2133/asset/olbannerleft.jpg?v=1&s=3d13800721e0d35da4d49e694f63a9d81054ca17)
1365-2133/asset/olbannerright.jpg?v=1&s=9ea9b247f2d7101244b2bef959a0874a886ec363)
The clinical evaluation of a new topical corticosteroid, clobetasol propionate
AN INTERNATIONAL CONTROLLED TRIAL†
Article first published online: 29 JUL 2006
DOI: 10.1111/j.1365-2133.1974.tb06385.x
Additional Information
How to Cite
SPARKES, C. G. and WILSON, L. (1974), The clinical evaluation of a new topical corticosteroid, clobetasol propionate. British Journal of Dermatology, 90: 197–203. doi: 10.1111/j.1365-2133.1974.tb06385.x
- †
Publication History
- Issue published online: 29 JUL 2006
- Article first published online: 29 JUL 2006
- Accepted for publication 14 June 1973
- Abstract
- References
- Cited By
SUMMARY
A new topically active corticosteroid, clobetasol propionate, has been investigated in the laboratory and in dermatological clinics to determine the best formulation for clinical use. Clinical trials involving 1150 patients were undertaken. In patients with bilateral psoriasis or eczema, clobetasol propionate, at a strength of 0.05%, was compared with betamethasone 17-valerate ointment and cream, fluclorolone acewnidc ointment and cream and fluocinonide (FAPG). The new steroid was shown to be effective therapeutically, especially in psoriasis. Each comparison in the trial was analysed independently and the following statistically significant differences were demonstrated.